Cargando…
Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy
Portal vein tumor thrombus (PVTT) is a frequent complication in hepatocellular carcinoma (HCC). HCC patients with PVTT have the characteristics of less treatment tolerance and poor prognosis. Immunotherapy, especially combined immunotherapy, has been successfully used in advanced HCC. However, there...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471014/ https://www.ncbi.nlm.nih.gov/pubmed/36119069 http://dx.doi.org/10.3389/fimmu.2022.999763 |
_version_ | 1784788970846027776 |
---|---|
author | Zhong, Kaihang Xu, Yuyan Cheng, Yuan Wen, Yaohong Cai, Lei He, Guolin Huang, Huakun Fu, Shunjun Zhong, Xuefeng Zheng, Yating Chen, Tingting Huang, Mengli Pan, Mingxin |
author_facet | Zhong, Kaihang Xu, Yuyan Cheng, Yuan Wen, Yaohong Cai, Lei He, Guolin Huang, Huakun Fu, Shunjun Zhong, Xuefeng Zheng, Yating Chen, Tingting Huang, Mengli Pan, Mingxin |
author_sort | Zhong, Kaihang |
collection | PubMed |
description | Portal vein tumor thrombus (PVTT) is a frequent complication in hepatocellular carcinoma (HCC). HCC patients with PVTT have the characteristics of less treatment tolerance and poor prognosis. Immunotherapy, especially combined immunotherapy, has been successfully used in advanced HCC. However, there are no recognized universally indicators that can predict response or resistance to immunotherapy for HCC. Herein, we reported a 58-year-old HCC patient with PVTT, cirrhosis and chronic viral hepatitis, who achieved complete response (CR) after combined immunotherapy (camrelizumab combined with sorafenib or regorafenib), according to his high enrichment of tumor-infiltrating immune cells and tertiary lymphoid structure (TLS). In this case, we revealed the characteristics of the baseline tumor immune microenvironment (TIME) in a HCC patient who responded well to combined immunotherapy, suggesting that TIME can be used to assist in clinical decision making of immunotherapy for HCC. |
format | Online Article Text |
id | pubmed-9471014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94710142022-09-15 Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy Zhong, Kaihang Xu, Yuyan Cheng, Yuan Wen, Yaohong Cai, Lei He, Guolin Huang, Huakun Fu, Shunjun Zhong, Xuefeng Zheng, Yating Chen, Tingting Huang, Mengli Pan, Mingxin Front Immunol Immunology Portal vein tumor thrombus (PVTT) is a frequent complication in hepatocellular carcinoma (HCC). HCC patients with PVTT have the characteristics of less treatment tolerance and poor prognosis. Immunotherapy, especially combined immunotherapy, has been successfully used in advanced HCC. However, there are no recognized universally indicators that can predict response or resistance to immunotherapy for HCC. Herein, we reported a 58-year-old HCC patient with PVTT, cirrhosis and chronic viral hepatitis, who achieved complete response (CR) after combined immunotherapy (camrelizumab combined with sorafenib or regorafenib), according to his high enrichment of tumor-infiltrating immune cells and tertiary lymphoid structure (TLS). In this case, we revealed the characteristics of the baseline tumor immune microenvironment (TIME) in a HCC patient who responded well to combined immunotherapy, suggesting that TIME can be used to assist in clinical decision making of immunotherapy for HCC. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9471014/ /pubmed/36119069 http://dx.doi.org/10.3389/fimmu.2022.999763 Text en Copyright © 2022 Zhong, Xu, Cheng, Wen, Cai, He, Huang, Fu, Zhong, Zheng, Chen, Huang and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhong, Kaihang Xu, Yuyan Cheng, Yuan Wen, Yaohong Cai, Lei He, Guolin Huang, Huakun Fu, Shunjun Zhong, Xuefeng Zheng, Yating Chen, Tingting Huang, Mengli Pan, Mingxin Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy |
title | Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy |
title_full | Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy |
title_fullStr | Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy |
title_full_unstemmed | Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy |
title_short | Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy |
title_sort | case report: primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471014/ https://www.ncbi.nlm.nih.gov/pubmed/36119069 http://dx.doi.org/10.3389/fimmu.2022.999763 |
work_keys_str_mv | AT zhongkaihang casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT xuyuyan casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT chengyuan casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT wenyaohong casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT cailei casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT heguolin casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT huanghuakun casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT fushunjun casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT zhongxuefeng casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT zhengyating casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT chentingting casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT huangmengli casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy AT panmingxin casereportprimaryhepatocellularcarcinomawithportalveintumorthrombuscharacterizedbyactivetumorimmunemicroenvironmentachievingacompleteresponsefollowingtreatmentofcombinedimmunotherapy |